Swiss biotech sector with robust growth
Last year, the biotechnology sector in Switzerland has continued its growth and proved to be a magnet for fresh capital and investment. This is revealed by the Swiss Biotech Report 2020.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2000 entries already.
Entries by Thomas Gabrielczyk
Viral vector one-stop-shop for gene and cell therapy
Many CDMOs have taken actions to meet the growing demand of viral vector development and manufacturing services for clinical trials, as well as for commercial scale production. While capacity is important, there are only a few companies who provide services across the entire supply and value chain. So, what should you expect when choosing a true one-stop-shop as a CDMO partner in the gene therapy space?
COVID-19: Novartis starts study on hyped malaria drug
Up to today, Novartis and Bayer announced donations of several millions of old antimalaria pills based on anecdotical reports of efficacy in COVID-19 patients. Now Novartis has started a study.
COVID 19: Halix ready for vaccine production
Dutch Halix BV will manufacture a ChAdOx1 nCoV-19 vaccine, developed at the University of Oxford .
Carbios SAS publishes PET recycling technology
For years, French Carbios SAS has worked to set up a process that effectively depolymerizes PET, one of the most common plastics. Now its process has been published.
Mobidiag’s COVID-19 test okayed for emergency use
Molecular diagnostics specialist Mobidiag Ltd has got emergency approval for its Amplidiag® COVID-19 molecular diagnostic test in Finland.
Is AMR the next, but hidden, crisis?
With the coronavirus pandemic mounting, experts are warning of AMR as being the next, hidden crisis.
Researchers reconstruct SARS-CoV-2 evolution
British researchers have tabled a phylogenetic tree showing different subtypes of SARS-CoV-2 developed in Asia, Europe and the US.
COVID-19: Solnatide approved for compassionate use
Austrian COVID-19 patients with severe lung dysfunction for the first time have a treatment option within a compassionate use program for Apeptico’s solnatide.
GE renamed Cytiva upon take-over by Danaher
Following the completion of Danaher’s €19.5bn take-over of GE Healthcare Life Sciences, GE’s CDMO arm is renamed Cytiva.